Oral misoprostol vs. vaginal misoprostol for termination of pregnancy with intrauterine fetal demise in the second‐trimester

Fadalla, F.A; Mirghani, Omer Ahmed; Adam, I.

doi:10.1016/j.ijgo.2003.12.006

Cited by 21 publications

(15 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seven trials compared various routes of misoprostol including oral versus sublingual route, oral versus vaginal route, and vaginal versus sublingual route (Table ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of the effectiveness, safety, and acceptability of medical management of intrauterine fetal death at 14–28 weeks of gestation

Cleeve

Fønhus

Lavelanet

2019

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Background Optimal dose, interval, and administration route of misoprostol with added benefit of mifepristone for management of second trimester intrauterine fetal death (IUFD) are not established. Objectives To assess effectiveness, safety, and acceptability of medical management of second trimester IUFD. Search strategy Research databases from January 2006 to October 2018. Selection criteria Randomized controlled trials with IUFD cases at 14–28 weeks of gestation. Data collection and analysis We screened and extracted data, assessed risk of bias, conducted analyses, and assessed overall certainty of the evidence. Main results Sixteen trials from 1695 citations. When misoprostol is used alone, 400 μg is more effective than 200 μg (RR 0.78; 95% CI, 0.66–0.92, moderate certainty evidence); the sublingual route is more effective than the oral route (RR 0.88; 95% CI, 0.70–1.11, low certainty evidence). There may be little to no difference between the sublingual and vaginal route (RR 0.93; 95% CI, 0.85–1.03, low certainty evidence). Certainty of evidence related to mifepristone–misoprostol regimens and safety and acceptability is very low. Conclusions Misoprostol 400 μg every 4 hours, sublingually or vaginally, may be effective. We cannot draw conclusions about safety and acceptability, or about the added benefits of mifepristone.

show abstract

“…Seven trials compared various routes of misoprostol including oral versus sublingual route, oral versus vaginal route, and vaginal versus sublingual route (Table ).…”

Section: Resultsmentioning

confidence: 99%

“…Eighty-three full texts were screened, of which 67 were excluded. Six additional trials [13][14][15][16][17][18] identified from three systematic reviews 6-8 were included. We contacted the authors of included trials where additional information was needed.…”

Section: Resultsmentioning

confidence: 99%

A systematic review of the effectiveness, safety, and acceptability of medical management of intrauterine fetal death at 14–28 weeks of gestation

Cleeve

Fønhus

Lavelanet

2019

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Comme les donné es de niveau de preuve é levé sont rares, notre analyse de la litté rature a tenu compte des ré sultats d'é tudes prospectives non randomisé es et ré trospectives bien mené es. La mé thodologie et les ré sultats des principales é tudes comparatives sont ré sumé s dans le Tableau 1 [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37].…”

Section: Modalite´s D'administration Du Misoprostol En Cas De Mfiu Auunclassified

Mort fœtale in utero au-delà de 14SA : induction du travail et obtention de la vacuité utérine

Beucher¹,

Dolley²,

Stewart

et al. 2015

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

“…Retained placenta or placental fragments is another complication of the use of misoprostol in the management of late intrauterine fetal death. This is seen more frequently with second‐trimester inductions for intrauterine fetal death than with those in the third trimester …”

Section: Women With Previous Caesarean Section and Other Uterine Scarsmentioning

confidence: 99%

“…This is seen more frequently with second-trimester inductions for intrauterine fetal death than with those in the third trimester. 10,37…”

Section: Women With Previous Caesarean Section and Other Uterine Scarsmentioning

confidence: 99%

The use of mifepristone and misoprostol in the management of late intrauterine fetal death

Nzewi

Araklitis

Narvekar

2014

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

Key content A combination of mifepristone and misoprostol is the gold standard treatment for induction of labour in women with late intrauterine fetal death. This article attempts to review the current best available evidence as well as provide an insight based on the available evidence regarding the dosing regimens and safety in women with a previous caesarean section. Learning objectives To review the pharmacokinetics, mode of action, efficacy, adverse effects, dose and route of administration of mifepristone and misoprostol. To review the safety of misoprostol in women with previous caesarean section and other uterine scars. Ethical issues To identify the most effective regimen with the fewest adverse effects. To balance the desire to achieve a quick and successful induction with the risk of complications including uterine rupture in women with previous uterine scars. To provide a sympathetic approach to women who are already emotionally stressed.

show abstract

Oral misoprostol vs. vaginal misoprostol for termination of pregnancy with intrauterine fetal demise in the second‐trimester

Cited by 21 publications

References 3 publications

A systematic review of the effectiveness, safety, and acceptability of medical management of intrauterine fetal death at 14–28 weeks of gestation

A systematic review of the effectiveness, safety, and acceptability of medical management of intrauterine fetal death at 14–28 weeks of gestation

Mort fœtale in utero au-delà de 14SA : induction du travail et obtention de la vacuité utérine

The use of mifepristone and misoprostol in the management of late intrauterine fetal death

Contact Info

Product

Resources

About